# An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

> **NCT07482813** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Paradigm Therapeutics** · enrollment: 80 (estimated)

## Conditions studied

- Epidermolysis Bullosa (EB)

## Interventions

- **DRUG:** SD-101 Dermal Cream (6%)

## Key facts

- **NCT ID:** NCT07482813
- **Lead sponsor:** Paradigm Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2027-07-19
- **Final completion:** 2027-08-19
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07482813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07482813, "An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07482813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*